1. Home
  2. CSTL vs TCMD Comparison

CSTL vs TCMD Comparison

Compare CSTL & TCMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$21.16

Market Cap

611.1M

Sector

Health Care

ML Signal

HOLD

Logo Tactile Systems Technology Inc.

TCMD

Tactile Systems Technology Inc.

HOLD

Current Price

$24.61

Market Cap

533.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSTL
TCMD
Founded
2007
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
611.1M
533.5M
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
CSTL
TCMD
Price
$21.16
$24.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
4
Target Price
$45.50
$36.00
AVG Volume (30 Days)
468.8K
335.9K
Earning Date
05-06-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
17.14
EPS
N/A
N/A
Revenue
$344,229,000.00
N/A
Revenue This Year
$2.42
$11.60
Revenue Next Year
$12.69
$9.14
P/E Ratio
N/A
N/A
Revenue Growth
3.66
N/A
52 Week Low
$14.59
$9.42
52 Week High
$44.28
$37.77

Technical Indicators

Market Signals
Indicator
CSTL
TCMD
Relative Strength Index (RSI) 47.27 49.25
Support Level $17.72 $22.78
Resistance Level $24.46 $27.19
Average True Range (ATR) 1.12 1.01
MACD 0.37 0.18
Stochastic Oscillator 74.65 55.81

Price Performance

Historical Comparison
CSTL
TCMD

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

About TCMD Tactile Systems Technology Inc.

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.

Share on Social Networks: